Modality.AI, Inc. has developed an automated, clinically validated multimodal system that utilizes conversational AI to monitor neurological and psychiatric conditions through speech and facial response analysis. This technology enables researchers and clinicians to collect accurate data and assess treatment responses in real-time, enhancing the efficiency of clinical trials and reducing costs.
Funding
$6.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional methods for monitoring neurological and psychiatric conditions often rely on subjective assessments and infrequent clinical visits, making it difficult to collect consistent, objective data and track treatment response effectively. This can lead to delays in optimizing treatment plans and inefficiencies in clinical trials.
Solution
Modality.AI offers an automated, clinically validated platform that uses conversational AI to monitor neurological and psychiatric conditions through the analysis of speech, facial expressions, and movement patterns. The system enables frequent and objective data collection in both clinical and remote settings, facilitating near real-time review of patient data and treatment response. By providing consistent and accurate assessments, Modality.AI aims to enhance the efficiency and reduce the costs associated with clinical trials, while also paving the way for more personalized and effective treatment strategies. The platform is designed to be HIPAA-compliant and can be accessed on devices with a browser, webcam, and microphone, without requiring any special software installation.
Target Audience
The primary target audience includes clinical researchers and sponsors of FDA clinical trials focused on neurological and psychiatric conditions, as well as clinicians seeking to improve patient monitoring and treatment outcomes.
Features
- Multimodal analysis of speech, facial expressions, and movement patterns using conversational AI
- Automated and objective assessment of neurological and psychiatric states
- Remote monitoring capabilities for convenient data collection at home or in the clinic
- Clinically validated system ensuring accuracy and reliability of results
- HIPAA-compliant platform to protect patient data privacy
- Real-time data review and treatment response monitoring
- Support for various neurological and psychiatric conditions, including ALS, Parkinson’s, depression, Alzheimer's, Autism, Huntington's Disease, Long Covid, Schizophrenia, and Mild Cognitive Impairment (MCI)
- Compatibility with computers, tablets, and smartphones via a standard web browser